Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales
03:05pm, Friday, 29'th Apr 2022 Zacks Investment Research
Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.
Can a decades-old antidepressant keep COVID-19 patients out of the hospital?
01:00pm, Thursday, 28'th Apr 2022 MarketWatch
It's one of several generic drugs that's being tested as a way to treat the virus.
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales
03:10pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.
GlaxoSmithKline earnings, revenue beat expectations
07:11am, Wednesday, 27'th Apr 2022 MarketWatch
Earnings per share were 35.6 pence in the quarter, a jump from 21.3 pence in the same quarter the year prior. Adjusted earnings per share--a closely-watched metric--were 32.8 pence, which the company
Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More
03:44pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
01:02pm, Monday, 25'th Apr 2022 Zacks Investment Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.
GlaxoSmithKline (GSK) Stock Moves -0.33%: What You Should Know
09:45pm, Thursday, 21'st Apr 2022 Zacks Investment Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.69, marking a -0.33% move from the previous day.
Glaxo's (GSK) NDA for Daprodustat Gets Accepted by the FDA
12:23pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
09:50pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.89, marking a -0.67% move from the previous day.
Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months
04:12pm, Monday, 18'th Apr 2022 Zacks Investment Research
Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.
Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag
02:55pm, Monday, 18'th Apr 2022 Zacks Investment Research
The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.
Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More
05:34pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.
Halozyme (HALO) to Acquire Antares for Auto Injector Platform
02:06pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.
M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus
02:03pm, Thursday, 14'th Apr 2022 Zacks Investment Research
We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates fo
Here's What This Regulatory News Could Mean for GlaxoSmithKline
11:08am, Thursday, 14'th Apr 2022 The Motley Fool
GlaxoSmithKline's anemia of chronic kidney disease drug could be just months away from authorization in the European Union.
